Response to “Evaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin‐Induced Ototoxicity”

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|96|2|158-158

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.2, 2014-08, pp. : 158-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin‐Induced Ototoxicity

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 156-157

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characteristics and Risk Factors of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients Detected by Distorsion Product Otoacoustic Emission

By  

Oncology, Vol. 70, Iss. 3, 2006-07 ,pp. : 177-184

Karger

Access to resources Recommend Favorite

Trichostatin A reduces cisplatin-induced ototoxicity through the STAT6 signaling pathway

By            

International Journal of Molecular Medicine, Vol. 36, Iss. 2, 2015-01 ,pp. : 493-500

Spandidos Publications

Access to resources Recommend Favorite

Genetic Markers of Cisplatin‐Induced Hearing Loss in Children

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 3, 2014-09 ,pp. : 296-298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk factors for cisplatin‐induced long‐term nephrotoxicity in pediatric cancer survivors

By  

PEDIATRICS INTERNATIONAL, Vol. 57, Iss. 3, 2015-06 ,pp. : 406-413

John Wiley & Sons Inc

Access to resources Recommend Favorite